Analyzing TriSalus Life Sciences (NASDAQ:TLSI) & Fresenius SE & Co. KGaA (OTCMKTS:FSNUY)

TriSalus Life Sciences (NASDAQ:TLSI) and Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability.

Analyst Ratings

This is a summary of current recommendations and price targets for TriSalus Life Sciences and Fresenius SE & Co. KGaA, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	0	0	0	0	N/A
Fresenius SE & Co. KGaA	0	2	2	0	2.50

Volatility & Risk

TriSalus Life Sciences has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Fresenius SE & Co. KGaA has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.

Insider & Institutional Ownership

2.6% of TriSalus Life Sciences shares are owned by institutional investors. 76.2% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares TriSalus Life Sciences and Fresenius SE & Co. KGaA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	N/A	N/A	-166.18%
Fresenius SE & Co. KGaA	0.71%	4.88%	2.02%

Earnings & Valuation

This table compares TriSalus Life Sciences and Fresenius SE & Co. KGaA’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$18.51 million	13.69	-$59.04 million	N/A	N/A
Fresenius SE & Co. KGaA	$24.01 billion	0.70	-$639.61 million	$0.11	68.37

TriSalus Life Sciences has higher earnings, but lower revenue than Fresenius SE & Co. KGaA.

Summary

Fresenius SE & Co. KGaA beats TriSalus Life Sciences on 6 of the 10 factors compared between the two stocks.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.